Page last updated: 2024-09-03

garenoxacin and Community Acquired Infection

garenoxacin has been researched along with Community Acquired Infection in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (50.00)	29.6817
2010's	6 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Mikamo, H; Mitsuyama, J; Nakagawa, S; Nomura, N; Shibata, T; Yamagishi, Y	1
Fukuda, Y; Fukushima, K; Hashiguchi, K; Higashiyama, Y; Imamura, Y; Inoue, Y; Izumikawa, K; Kobayashi, T; Koga, H; Kohno, S; Kondo, A; Mikushi, S; Miyazaki, T; Morinaga, Y; Mukae, H; Nagayoshi, Y; Nakamura, S; Saijo, T; Sasaki, E; Takazono, T; Yamamoto, K; Yanagihara, K; Yoshida, M	1
Fujita, J; Higa, F; Hiramatsu, K; Kadota, J; Kohno, S; Tateyama, M; Tokimatsu, I; Yamamoto, Y; Yanagihara, K	1
Hosono, H; Ishida, T; Izumikawa, K; Kohno, S; Kushimoto, S; Miyashita, N; Watanabe, A	2
Hatano, M; Ito, M; Kondo, S; Maruyama, Y; Miwa, T; Murono, S; Nakanishi, S; Wakisaka, N; Yoshizaki, T	1
Biedenbach, DJ; Jones, RN	1
Hammerschlag, MR; Reznik, T; Roblin, PM	1
Ambrose, PG; Bello, A; Costanzo, C; Echols, R; Gajjar, DA; Grasela, DM; Grasela, TH; Ludwig, EA; Phillips, L; Russo, R; Van Wart, S	1
Fritsche, TR; Jones, RN; Sader, HS; Stilwell, MG	2
Hoban, DJ; Noreddin, AM; Ostroski, M; Reese, AA; Zhanel, GG	1

Trials

3 trial(s) available for garenoxacin and Community Acquired Infection

Article	Year
The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2019, Volume: 25, Issue:11 Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Japan; Male; Pneumonia; Quinolones	2019
Early switch therapy from intravenous sulbactam/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2013, Volume: 19, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Injections, Intravenous; Japan; Male; Middle Aged; Pneumonia, Bacterial; Recurrence; Sulbactam; Treatment Outcome	2013
Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections. Auris, nasus, larynx, 2012, Volume: 39, Issue:5 Topics: Adult; Aged; Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Laryngitis; Male; Middle Aged; Otitis Media; Pharyngitis; Respiratory Tract Infections; Sinusitis; Treatment Outcome	2012

Other Studies

9 other study(ies) available for garenoxacin and Community Acquired Infection

Article	Year
Proposed Pharmacokinetic-Pharmacodynamic Breakpoint of Garenoxacin and Other Quinolones. Japanese journal of infectious diseases, 2017, Nov-22, Volume: 70, Issue:6 Topics: Administration, Oral; Anti-Bacterial Agents; Area Under Curve; Community-Acquired Infections; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Monte Carlo Method; Pneumonia, Bacterial; Quinolones; Streptococcus pneumoniae	2017
Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:9 Topics: Adult; Anti-Bacterial Agents; Chlamydophila Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Mycoplasma pneumoniae; Pneumonia, Bacterial; Pneumonia, Mycoplasma; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Tablets	2014
Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2014, Volume: 20, Issue:9 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Japan; Male; Microbial Sensitivity Tests; Middle Aged; Pneumococcal Infections; Pneumonia, Bacterial; Product Surveillance, Postmarketing; Prospective Studies; Quinolines; Streptococcus pneumoniae; Tablets	2014
Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). Diagnostic microbiology and infectious disease, 2003, Volume: 45, Issue:4 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Microbial; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Indoles; Male; Microbial Sensitivity Tests; Moraxella catarrhalis; North America; Quinolones; Respiratory Tract Infections; Sensitivity and Specificity; Streptococcus pneumoniae	2003
In vitro activity of garenoxacin against recent clinical isolates of Chlamydia pneumoniae. International journal of antimicrobial agents, 2003, Volume: 21, Issue:6 Topics: Adult; Anti-Infective Agents; Canada; Chlamydophila Infections; Chlamydophila pneumoniae; Community-Acquired Infections; Fluoroquinolones; Humans; Indoles; Japan; Microbial Sensitivity Tests; Pneumonia, Bacterial; Quinolones; United States	2003
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:12 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Bronchitis; Community-Acquired Infections; Drug Interactions; Female; Fluoroquinolones; Food-Drug Interactions; Humans; Male; Mass Spectrometry; Middle Aged; Models, Biological; Pneumonia; Population; Reproducibility of Results; Respiratory Tract Infections; Sinusitis	2004
Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values. Diagnostic microbiology and infectious disease, 2007, Volume: 58, Issue:1 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moraxella catarrhalis; Respiratory Tract Infections; Streptococcus pneumoniae	2007
Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae. Diagnostic microbiology and infectious disease, 2007, Volume: 58, Issue:1 Topics: Anti-Bacterial Agents; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Hospitalization; Humans; Microbial Sensitivity Tests; Pneumonia, Bacterial; Pneumonia, Pneumococcal; Streptococcus pneumoniae	2007
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis. Clinical therapeutics, 2007, Volume: 29, Issue:12 Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Community-Acquired Infections; Fluoroquinolones; Gemifloxacin; Humans; Monte Carlo Method; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Respiratory Mucosa	2007